Gilead nears up to $2 billion buyout of biotech Ouro Medicines, FT reports Investing March 23, 2026 Gilead nears up to $2 billion buyout of biotech Ouro Medicines, FT reports
Australia’s BlueScope hits 17-year high on $8.8 billion buyout bid from SGH, Steel Dynamics finance January 6, 2026 Australia’s BlueScope hits 17-year high on $8.8 billion buyout bid from SGH, Steel Dynamics
